US5698549A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating hyperactive voiding with calcium channel blockers
Assignee: UVA Licensing and Ventures Group
•
Filing: 1995-06-07
•
Granted: 1997-12-16
•
Expires: 2015-06-07
Abstract
Abstract The instant invention discloses a method of treating hyperactive voiding associated with excessive nerve growth factor production and nerve growth in patients by administering a Ca++ channel blocker. The Ca++ channel blockers verapamil and diltiazem can be administered systemically to treat hyperactive voiding, such as is associated with benign prostatic hyperplasia and interstitial cystitis.
Inventors
- 👤 William D. Steers
- 👤 Jeremy B. Tuttle
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:54
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N2333/00; G01N2333/435; G01N2333/475; G01N2333/48; G01N2333/50; G01N2333/503
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
32 words
A method of treating hyperactive voiding associated with excessive nerve growth factor production and nerve growth in a patient in need thereof comprising administering to said patient a Ca ++ channel blocker.
Claim 2
Independent Claim
32 words
A method of treating hyperactive voiding associated with excessive nerve growth factor production and nerve growth in a patient in need thereof comprising administering to said patient a Ca ++ channel blocker.
Claim 3
Dependent Claim
14 words
The method according to claim 1 wherein said ca ++ channel blocker is verapamil.
Claim 4
Dependent Claim
14 words
The method according to claim 1 wherein said Ca ++ channel blocker is diltiazem.
Claim 5
Dependent Claim
16 words
The method according to claim 1 wherein said hyperactive voiding is associated with benign prostatic hyperplasia.
Claim 6
Dependent Claim
15 words
The method according to claim 1 wherein said hyperactive voiding is associated with interstitial cystitis.
Claim 7
Dependent Claim
14 words
The method according to claim 1 wherein said Ca ++ blocker is administered systemically.
References Cited (Backward Citations)
US5354765A
Cited
US5252337A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-12-15 | 2001-06-16 | 2001-12-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-12-15 | 2005-06-16 | 2005-12-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-12-15 | 2009-06-16 | 2009-12-16 | $7700.00 | Window Closed / Lapsed |